Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonmyeloablative Haploidentical PBSC Transplantation for Sickle Cell Disease
NCT03077542Phase 2Active, not recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Apr 2017
- Primary completion
- Jul 2023
- Modality
- Nanoparticles, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pentostatin, cyclophosphamide, alemtuzumab, nab-sirolimus in sickle cell disease (SCD), sponsored by National Heart, Lung, and Blood Institute. Started Apr 2017; status: active, not recruiting.
02
Drugs
pentostatincyclophosphamidealemtuzumabnab-sirolimus
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03077542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03077542.